{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:31:00Z","timestamp":1791873060788,"version":"4.3.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported so far. Here we report two cases of semaglutide-associated depression. One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide. The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment. Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1238353","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:18:06Z","timestamp":1693343886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Case Report: Semaglutide-associated depression: a report of two cases"],"prefix":"10.3389","volume":"14","author":[{"given":"Jia-Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/dom.14500","article-title":"Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection","volume":"23","author":"Andreasen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.13229","article-title":"Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy","volume":"45","author":"Bzowyckyj","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s40200-021-00899-9","article-title":"Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists","volume":"20","author":"Okamoto","year":"2021","journal-title":"J Diabetes Metab Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/a-2007-2061","article-title":"Real-world use of once-weekly Semaglutide in type 2 diabetes: results from Semaglutide real-world evidence (SURE) Germany","volume":"131","author":"Menzen","year":"2023","journal-title":"Exp Clin Endocr Diab"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.xkme.2022.100561","article-title":"Semaglutide-associated acute interstitial nephritis: a case report","volume":"4","author":"Borkum","year":"2022","journal-title":"Kidney Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials","volume":"19","author":"O'Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous Semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA J Am Med Assoc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref13","article-title":"Health Topic-Facts about overweight and obesity","year":"2023"},{"key":"ref14","article-title":"Health Topic-Diabetes","year":"2023"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Brit J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"599646","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like Peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"E1367","DOI":"10.1152\/ajpendo.00413.2013","article-title":"The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA\/kainate receptors","volume":"305","author":"Mietlicki-Baase","year":"2013","journal-title":"Am J Physiol Endocrinal Metab"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"104772","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochem Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.aaz5891","article-title":"Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work","volume":"367","author":"Westbrook","year":"2020","journal-title":"Science"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1238353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:18:08Z","timestamp":1693343888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1238353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2023.1238353"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1238353","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"article-number":"1238353"}}